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Abstract
Barrett’s Esophagus is an increasingly common disease that is strongly associated with reflux of
stomach acid and usually a hiatus hernia. Barrett’s Esophagus strongly predisposes to esophageal
adenocarcinoma (EAC), a tumour with a very poor prognosis. We have undertaken the first
genome-wide association study on Barrett’s Esophagus, comprising 1,852 UK cases and 5,172 UK
controls in discovery and 5,986 cases and 12,825 controls in the replication. Two regions were
associated with disease risk: chromosome 6p21, rs9257809 (Pcombined=4.09×10−9, OR(95%CI)
=1.21(1.13-1.28)) and chromosome 16q24, rs9936833 (Pcombined=2.74×10−10, OR(95%CI)
=1.14(1.10-1.19)). The top SNP on chromosome 6p21 is within the major histocompatibility
complex, and the closest protein-coding gene to rs9936833 on chromosome 16q24 is FOXF1,
which is implicated in esophageal development and structure. We found evidence that the genetic
component of Barrett’s Esophagus is mediated by many common variants of small effect and that
SNP alleles predisposing to obesity also increase risk for Barrett’s Esophagus.
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Barrett’s Esophagus is one of the most common pre-malignant lesions in the Western world.
It affects over 2% of the adult population and, unlike bowel polyps, lacks any proven
effective therapy1. In the majority of cases, Barrett’s Esophagus is associated with chronic
gastro-esophageal reflux disease (GERD), including esophagitis 2,3. In addition there are
structural changes, mainly hiatus hernia, in the lower esophagus in over 80% of patients4.
This allows both acid and bile to remain immediately adjacent to the esophageal epithelium.
The measured annual risk of esophageal adenocarcinoma (EAC) in Barrett’s Esophagus
patient’s varies widely but is approximately 0.4-1% 5-7. Notably the incidence of EAC has
been rising by 3% each year for the last 30 years; it is now the fifth commonest cancer in the
UK 8. Despite modern multimodality therapy, the prognosis of EAC remains poor, with a
9-15% 5-year survival 9,10.
The etiology of Barrett’s Esophagus is not well characterised. Environmental factors, such
as diet, are weakly associated with GERD, Barrett’s Esophagus and EAC, and obesity is a
known risk factor for all three conditions11. There is also evidence implicating genetic
factors: the relative risks are increased 2-4 fold for GERD, Barrett’s Esophagus and EAC
when one first-degree relative is affected12-17. A segregation analysis of 881 pedigrees of
familial Barrett’s Esophagus supports an incompletely dominant inheritance model with a
polygenic component18. Extensive candidate gene and linkage searches have, to date, failed
to identify genetic variants that are associated with risk of Barrett’s Esophagus19.
As part of the Wellcome Trust Case Control Consortium 2 (WTCCC2) study of 15 common
disorders and traits, we present the results of the first genome-wide association study of
Barrett’s Esophagus susceptibility. Using a discovery cohort from the UK (with case
samples from Aspirin and Esomeprazole Chemoprevention Trial of Cancer in Barrett’s
Oesophagus (AspECT)20), and five replication cohorts (including case samples from
CHemoprevention Of Premalignant Intestinal Neoplasia (ChOPIN) and Esophageal
Adenocarcinoma GenEtics Consortium (EAGLE) studies9,20), we identified two variants
associated with Barrett’s Esophagus, each with combined evidence at P<5×10−8. The
analysis workflow is outlined in Supplementary Figure 1 and characteristics of the case and
control samples used can be found in Supplementary Table 1 and Online Methods.
For the discovery analysis, cases with histologically confirmed Barrett’s Esophagus (see
methods) were recruited from sites across the UK (Supplementary Table 2). Population
controls were taken from the WTCCC2 common set of 1958 Birth Cohort (58C) and
National Blood Service (UKBS) samples as previously described21. The case individuals
were genotyped on the Illumina 660W-Quad array and controls were genotyped on the
Illumina custom Human 1.2M-Duo array, with the analysis performed on the overlapping
set of SNPs. Following quality control (see Online Methods, Supplementary Note,
Supplementary Figure 2 and Supplementary Table 3), a total of 521,744 SNPs typed in
1,852 cases and 5,172 controls (2,499 UKBS and 2,673 58C) were included in the discovery
analysis.
Association analysis was carried out under a logistic regression model as implemented in
SNPTEST. The genomic over-dispersion factor22 λ was 1.10 and this was reduced to 1.05
when incorporating the first principal component as a covariate, suggesting that population
structure was not a major problem in the discovery analyses (Supplementary Figure 3). For
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all of the following results presented, unless otherwise stated, the first principal component
was used as a covariate.
Following analysis of the genome-wide association results (Figure 1), we adopted a staged
approach to replication, outlined below and in Supplementary Figure 1.
Stage 1
100 SNPs that showed evidence of association in the discovery data (at P<5×10−4) were
analysed in another UK sample set. This comprised 1,105 cases from ChOPIN and EAGLE
and 4,421 controls from the 58C control dataset, all genotyped on the Illumina
Immunochip23 (WTCCC2 contributed SNPs to the Immunochip design to allow for its
replication studies, and the set of 100 SNPs followed up in our Stage 1 replication were all
on the Immunochip), and a further set of 2,578 UK controls (the People of the British Isles
(PoBI) collection 24) genotyped on the Illumina custom Human 1.2M-Duo array. Results of
this first stage of replication are shown in Supplementary Table 4.
Stage 2
The 16 top SNPs (Pcombined<10−5) from meta-analysis of the discovery and Stage 1
replication were replicated in silico in a Dutch collection of 473 cases and 1,780 controls
genotyped on the Immunochip23. Results from Stage 2 replication are shown in
Supplementary Table 5.
Stage 3
Two SNPs with Pcombined<5×10−8 after Stage 2 replication (rs9257809 on chromosome
6p21 and rs9936833 on chromosome 16q24) were studied in three additional replication
sample sets. They were directly genotyped in an Irish cohort of 245 cases and 473 controls
and a UK cohort of 1,765 cases and 1,586 controls, and data from these SNPs was retrieved
from the BEACON consortium for 2,398 cases and 2,167 controls from European,
Australian and American individuals with European ancestry.
After these three stages of replication, the two SNPs on chromosome 6p21 and 16q24
showed compelling evidence for association, with combined P values of 4.09×10−9 for
rs9257809, OR(95%CI)=1.21(1.13-1.28) and 2.74×10−10 for rs9936833, OR(95%CI)
=1.14(1.10-1.19) (Table 1, Figures 2, 3).
We performed tests for pair-wise interaction (see Supplementary Note) in the discovery data
between all pairs of the 16 SNPs taken forward to Stage 2 replication (Supplementary Table
5), but no significant interactions (P<0.01) were found.
Imputation was carried out in the discovery data for the chromosome 6p21 and 16q24
regions, using the 1000 Genomes June 2010 CEU reference panel. In each case, rs9257809
and rs9936833 respectively remained as the strongest signal of association in each region
(Supplementary Figure 4).
The lead SNP on 16q24, rs9936833, maps 24kb from the spliced, non-coding transcript
LOC732275. The closest coding gene, 141kb towards the telomere, is FOXF1, a forkhead
family transcription factor that acts in the hedgehog signaling pathway. FOXF1 is known to
have a role in the development of the gastrointestinal tract and has been reported to cause
esophageal structural alterations, especially atresia, when inactivated 25. The region around
rs9936833 contains multiple binding sites for specific transcription factors, such as FOXP2,
that are known to control FOXF1 expression (assessed using ENCODE data, see URLs).
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The lead SNP on 6p21, rs9257809, lies on the telomeric edge of the major
histocompatibility complex (MHC) region between olfactory receptor genes OR2D12 and
OR2D13. It is in strong long-range linkage disequilibrium (r2>0.6 calculated in the control
data) with SNPs over 1 Mb away, including two at which Stage 2 replication was attempted,
rs13211507 (Pcombined =8.77×10−9) and rs9262143 (Pcombined=2.18×10−8). When
conditioning on rs9257809, no other SNP in the MHC was significant at P<10−5.
To further investigate the SNP signal in the MHC region, we took two approaches:
GENECLUSTER, which is a Bayesian tree building method26,27; and HLA*IMP, which is a
method for imputing classical HLA alleles from SNP data28. Both methods provided
evidence of association in the discovery data for reduced risk conferred by three classical
HLA alleles that are in strong LD with each other (HLA-C*07:01, HLA-A*01:01 and HLA-
B*08:01), see Supplementary Table 6. However, conditional analysis suggested that
rs9257809 better captures the association in our discovery data and none of these three
classical HLA alleles showed an association signal in the replication data (P>0.1,
Supplementary Table 6).
We used standard UK criteria, in accordance with the British Society of Gastoenterology,
for diagnosis of Barrett’s Esophagus. However some countries use the American College of
Gastroenterology criteria that require the presence of intestinal metaplasia for the diagnosis
of Barrett’s Esophagus. To investigate this, we analysed the two replicated loci using only
the subset of discovery and replication cases (86%) with histological evidence of intestinal
metaplasia. Both signals remained significant, with combined evidence across discovery and
all stages of replication of P<5×10−8 (Supplementary Table 7A and 7B).
We also investigated associations with the related quantitative traits of circumferential
extent (C) and maximal extent (M) of the length of Barrett’s segment. In the discovery
cohort, the C measurement was available for 1,744 cases, and the M measurement for 1,618
cases. In a linear regression analysis of cases, neither SNP showed evidence of association
with C or M status (for rs9936833, P=0.63 and P=0.87 respectively; for rs925809, P=0.10
and P=0.09 respectively). We then extended the C and M analysis genome-wide. No SNP
reached P<10−6 in the analysis of C. One SNP (rs1023313) reached P<10−6 in the analysis
of M, but this association was not confirmed in Stage 1 or Stage 2 replication (see
Supplementary Table 8).
There is an established sex bias in BE susceptibility, with men at greater risk than
women3,29. The ratio of males to females is 4:1 in our case discovery data. To see whether
there might be sex-specific effects of any predisposition SNPs, we performed a sex-stratified
analysis for the 16 SNPs analysed in Stage 2 (Supplementary Table 9). The SNP showing
the most evidence for a sex-specific effect from the combined discovery and Stage 1 and 2
replication was rs9257809. The association signal was stronger in males than females
(uncorrected P=0.01 for difference of effects between sexes), corresponding to a male odds
ratio of 1.38 (95%CI 1.25-1.53, Pcombined=1.71×10−10) and a female odds ratio of 1.11
(95%CI 0.95-1.30, Pcombined=0.19), see Supplementary Note for further details. This finding
warrants further investigation.
Previous genome-wide association studies of common diseases or phenotypes have found
evidence for a model where many common variants of small effect influence risk 30,31. We
looked for these en masse effects in Barrett’s Esophagus using two methods (see Online
Methods). Firstly, taking the top K SNPs (for different values of K) in independent regions
in the discovery data, we performed a sign test to see whether there was an excess (over the
proportion expected under the null of 50%) of SNPs for which the effect was in the same
direction in the Stage 1 replication data. Secondly a disease-score test analysis was
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undertaken, as described by the International Schizophrenia Consortium 30. Both methods
found evidence of an excess of SNPs that have the same risk allele in both cohorts. The
strongest evidence in the sign test was for the top 1,100 SNPs, for which the sign test gave
Puncorrected=2.30×10−5 (Supplementary Figure 5). From the disease-score analysis, the
strongest evidence was for the top 1,710 SNPs, for which Puncorrected=7.07×10−11
(Supplementary Figure 6). Both analyses thus implicate a large number of common SNPs of
small effect in susceptibility to Barrett’s Esophagus.
There is a well-established link between Barrett’s Esophagus and obesity32,33. To
investigate whether this may in part reflect genetic effects, we repeated the sign test at 40 of
the SNPs that have been found to be associated with either Body Mass Index (BMI) or
Waist Hip Ratio (WHR), where genotype data or tag SNPs were available in our discovery
samples 34-38. In our discovery data, a total of 29 out of 40 BMI/WHR-associated SNPs (14
genotyped, 15 tagging, Supplementary Tables 10A and 10B) shared the same risk alleles in
Barrett’s Esophagus as they did for BMI/WHR (P=6.42×10−3).
Our results provide direct evidence that Barrett’s Esophagus aetiology has a genetic
component. Inference as to the underlying genes must be cautious, especially for the variant
(tagged by rs9257809) in the gene-rich MHC region in which linkage disequilibrium is long-
range and complex. However, the location of the other associated SNP, rs9936833, near
FOXF1 suggests a role for structural factors in the esophagus and stomach as a disease-
predisposing factor, consistent with the evidence that changes such as hiatus hernia are
known to be strongly associated with Barrett’s Esophagus. We also found evidence to show
that body weight SNPs are more likely than by chance to show effects in the same direction
in Barrett’s Esophagus, suggesting that genetic effects may in part underpin the
epidemiological observation that BMI is a risk factor for Barrett’s Esophagus 39. Given that
Barrett’s Esophagus is an accepted status as a precursor lesion, the SNPs that we have
identified could also be de facto risk factors for esophageal adenocarcinoma and may give
clues as to the biology of both of these important phenotypes.
Online Methods
Samples
Cases from Discovery, Stages 1 and 2 replication, and Stage 3 UK and Irish—
For the discovery, we ascertained cases of histologically-confirmed Barrett’s Esophagus
through the United Kingdom-based ASPECT clinical trial of proton pump-inhibitor
(esomeprazole) and aspirin as preventive agents for progression of Barrett’s Esophagus to
EAC20. UK, Irish and Dutch replication cases were from the Chemoprevention of
Premalignant Intestinal Neoplasia (ChOPIN) genetic study and the Esophageal
Adenocarcinoma GenE (EAGLE) consortium9. Replication cases were diagnosed with
Barrett’s Esophagus with lengths of at least 1cm (CIMI) circumferential Barrett’s Esophagus
or at least a 2cm tongue (C0M2) according to the Prague criteria40. Case collection was in
accordance with the British Society of Gastoenterology criteria41, the standard practice for
collaborating Histopathologists in the UK and much of Europe. We found that 90% of our
discovery samples (for which full clinico-pathological data were available) had evidence of
intestinal metaplasia and therefore also met the American College of Gastroenterology
criteria that are widely used in the USA42 . For full details of the ethnicity, age and sex
distributions and Prague criteria measurements of the cases see Supplementary Table 1.
Discovery: The full data set comprised of 1,991 cases and 5,667 controls. After QC, 1,852
cases and 5,172 controls were analysed. Controls were taken from the WTCCC2 set, made
up of samples from the 1958 British Birth Cohort (58C) and the National Blood Service
collection (UKBS). Samples were genotyped at the Wellcome Trust Sanger Institute
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(WTSI), cases on the Illumina Human660W-Quad array, and controls on the Illumina
custom Human 1.2M-Duo. The primary analysis was performed on the overlapping set of
SNPs.
Stage 1: After QC, the UK replication totalled 1,105 cases and 6,819 controls. The controls
were from the PoBI cohort (2,578)24 and 58C (4,241) samples that were not genotyped in
the discovery phase. The case and 58C control samples were genotyped on the Illumina
Immunochip and the PoBI samples were genotyped on the Illumina custom Human 1.2M-
Duo array. The Immunochip is a custom-designed chip containing 196,524 SNPs in total, of
which ~2,400 were selected on the basis of our discovery GWAS study.
Stage 2: The Dutch replication cohort consisted of 473 cases and 1,780 controls. These
samples were all genotyped on the Illumina Immunochip but in two separate locations; the
case samples were genotyped at WTSI and the control samples were genotyped as described
in a previous report43.
See Supplementary Note for information on DNA sample preparation.
Circumferential and Maximal Extent Phenotypes—Length of the Barrett’s segment
was available for a subset of discovery and replication phase samples. Where baseline
measurements were not available, the earliest measurement taken after baseline was used. A
small number of cases were excluded on the basis of reporting errors (if C >M or if either
value exceeded 25cm). Of the discovery phase individuals after quality control, 1,744 had C
measurements and 1,618 had M measurements, C mean=4.05 (range 0-22); M mean=4.60
(range 1-24). M measurements were available for 1,015 of the Stage 1 replication (M
mean=4.66 (range 1-23)) and for 240 of the Stage 2 replication (M mean=4.44 (range
1-15)). Both C and M phenotypes were square-root transformed prior to analysis, to improve
the fit of the linear regression model.
Stage 3
Irish Replication: The Irish replication cohort consisted of 245 cases and 473 controls.
Cases were provided by St James’s Hospital and Mater Misericordiae University Hospital
Dublin as part of EAGLE. Controls were provided by Trinity Biobank. 168 cases were
genotyped on the Illumina Immunochip at WTSI. rs9257809 and rs9936833 were genotyped
in 77 cases and all controls using competitive allele-specific PCR KASPar chemistry
(KBiosciences Ltd, Hertfordshire, UK). Primers, probes and conditions used are available on
request. Genotyping quality control was tested using duplicate DNA samples within studies
and SNP assays, together with direct sequencing of subsets of samples to confirm
genotyping accuracy. For all SNPs, >99% concordant results were obtained.
UK Replication 2: 1,765 cases were ascertained using the diagnostic criteria and sampling
from ASPECT as described above for discovery. 1586 controls were collected as part of the
Colorectal Tumour Gene Identification (CoRGI) consortium44. Controls were spouses or
partners unaffected by cancer and without a personal family history (to 2nd degree relative
level) of colorectal neoplasia. All were of white UK ethnic origin, 45% male; mean age 45.1
years, SD±15.9. All samples were genotyped using KASPar competitive allele-specific PCR
as described above.
BEACON Replication: 2,398 cases and 2,167 controls were analyzed. Samples were
collected as part of a GWAS study (BEAGESS) undertaken by the BEACON collaboration.
Samples were collected from sites in Australia (cases n=325, controls n=561), Europe
(England, Ireland, Sweden; cases n=363, controls n=333), and North America (Canada,
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United States, cases n=1,710, controls n=1,273). Samples were genotyped at the Fred
Hutchinson Cancer Research Center (FHCRC) on the Illumina Omni1M Quad.
Quality control
Samples—As previously described21,45, we identified and removed samples whose
genome-wide patterns of diversity differed from those of the collection at large, interpreting
them as likely to be due to biases or artefacts. See Supplementary Note for further details.
Following sample quality control our final discovery dataset consisted of 1,852 cases and
5,172 controls (Supplementary Table 3).
SNPs—For all arrays, normalised probe intensities were exported using the BeadStudio
program and genotypes were called at the WTSI using Illuminus46. SNPs were excluded
from analysis if in any of the data sets (58C, UKBS or cases) they had: a very low minor
allele frequency (defined as <0.01%); extreme departures from Hardy-Weinberg equilibrium
(P<10−20); showed a strong plate effect (P<10−6). SNPs were also excluded if the observed
statistical (Fisher) information about the allele frequency was less than 98% of the
information contained in a hypothetical sample of the same size and expected MAF but with
no missing data. 45 SNPs were removed following visual inspection of cluster plots. In total
521,744 autosomal SNPs were available for analysis after quality control.
To confirm genotyping accuracy of the different platforms used in the study, 5% of the UK,
Irish and Dutch samples typed on each platform were re-genotyped at rs9257809 and
rs9936833 using competitive allele-specific PCR KASPar. Concordance was >99%
(Supplementary Table 11) suggesting genotyping robustness across platforms.
HLA Imputation
Classical HLA alleles were imputed using HLA*IMP 28. Further details of this can be found
in Supplementary Note.
Statistical analysis
Genome-wide case-control analysis was performed using frequentist tests, under a missing
data logistic regression model, as implemented in SNPTEST. Unless otherwise stated, we
assumed a multiplicative model for allelic risk by encoding the genotypes at each SNP as a
discrete explanatory variable with an indicator of case status as the binary response and the
first principal component as a covariate (see Supplementary Note). Quantitative C and M
measurements were analysed using frequentist tests under a missing data linear regression
model, as implemented in SNPTEST. To combine the evidence of association across the
discovery and replication datasets we conducted an inverse-variance weighted fixed effect
meta-analysis in the statistical package R (see Supplementary Note). To test for interactions
(see Supplementary Note), between SNPs, or between a SNP and sex, and to compare
models which include additional SNPs or classical HLA alleles as predictors, we used
logistic regression models implemented in R. These analyses used thresholded (posterior
probability > 0.9) genotype calls.
SNP Imputation was performed using IMPUTE247, which adopts a two-stage approach
using both a haploid reference panel and a diploid reference panel.
BEACON data was analysed under an additive logistic regression model including the first
four principal components as covariates (see Supplementary Note). Genomic inflation λ was
1.037.
and Page 7
Nat Genet. Author manuscript; available in PMC 2013 April 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
En Masse analysis was carried out on the discovery and Stage 1 data. In order to reduce
possible population structure (such analyses are sensitive to this), we restricted the Stage 1
control set to the 58C individuals. SNPs with MAF > 0.01 which were genotyped in both the
discovery (Illumina 670K and Illumina custom Human 1.2M-Duo) and the replication
(Illumina Immunochip) were pruned to remove strong linkage disequilibrium. This was
done by ranking the SNPs by Bayes factor calculated under an additive model in SNPTEST,
and successively selecting SNPs from the top so that they were at least 0.125cM plus 25kb
away from any SNPs that had already been selected. We obtained 7,673 SNPs from a total
of 28,972 (after quality control) that were typed in discovery and UK Immunochip data. For
the K SNPs showing the strongest signal of association, the sign test compares the direction
of effect of each SNP in the discovery and replication samples. Using a likelihood-ratio test
we compared the null model where the probability of the same direction of effect is assumed
to be a half, to a model where the probability is not a half (two sided).
The disease-score test aims to measure indirectly the collective effect of many weakly
associated alleles. We determined the risk allele and odds ratio for each pruned SNP from
the discovery data as described above. Then, we used the top K SNPs to calculate the
“score” for each individual in the replication data as the number of risk alleles carried by
each individual weighted by the log of the odds ratio estimated from the discovery data.
Under the null hypothesis, the risk alleles and odds ratios in the discovery and replication
samples are independent. We tested a logistic regression model of disease status on the score
in the replication data, conditioning on the first principal component, to control for
population structure, and the number of missing genotypes (called with maximum
probability < 0.9), to control for potential differences in genotyping rate, as covariates.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Plot of the genome-wide association results after fitting the multiplicative model in
SNPTEST. Results shown for the 521,744 SNPs passing quality control filters.
Chromosomes are coloured dark blue and light blue alternatively, as labelled on the x-axis.
The y-axis shows the −log10 P values. Regions in red show the loci newly identified as
associated with BE, as described in Table 1.
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Figure 2.
Regional association plot of the associated loci as detailed in Table 1, showing the signal at
the lead SNP. The −log10 P values for the SNPs are shown on the upper part of each plot.
SNPs are coloured based on their r2 with the labelled hit SNP which has the smallest P value
in the region. r2 is calculated from the 58C data. The bottom section of each plot shows the
fine scale recombination rates estimated from individuals in the HapMap population, and
genes are marked by horizontal blue lines.
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Figure 3.
Forest plots showing evidence for association at each of the loci described in Table 1. The
effect size and 95% CI are shown to the right of the cohort label for the discovery and
replication cohorts and for the fixed effects meta-analysis. The red dashed line marks the
effect size calculated from the fixed effects meta-analysis. P values for each cohort are
shown at the right of the plot and the meta-analysis P value is also given, all P values are
two-sided.
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